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Antipsychotic drugs, originally developed to treat schizophrenia, are used to treat psychosis, 
agitation and aggression in Alzheimer’s disease. In the absence of dopamine D2/3 receptor 
occupancy data to inform antipsychotic prescribing for psychosis in Alzheimer’s disease, the 
mechanisms underpinning antipsychotic efficacy and side effects are poorly understood. This 
study used a population approach to investigate the relationship between amisulpride blood 
concentration and central D2/3 occupancy in older people with Alzheimer’s disease by 
combining (i) Pharmacokinetic data (280 venous samples) from a phase I single (50mg) dose 
study in healthy older people (n=20, 65-79 years) (ii) Pharmacokinetic, [18F]fallypride D2/3 
receptor imaging and clinical outcome data on patients with Alzheimer’s disease who were 
prescribed amisulpride (25-75mg daily) to treat psychosis as part of an open study (n=28; 69-
92 years; 41 blood samples, five pre-treatment scans, 19 post-treatment scans) (iii) 
[18F]fallypride imaging of an antipsychotic free Alzheimer’s disease control group (n=10, 78-
92 years), to provide additional pre-treatment data. Non-linear mixed effects modelling was 
used to describe pharmacokinetic-occupancy curves in caudate, putamen and thalamus. 
Model outputs were used to estimate threshold steady state blood concentration and 
occupancy required to elicit a clinically relevant response (>25% reduction in scores on 
delusions, hallucinations and agitation domains of the Neuropsychiatric Inventory) and 
extrapyramidal side-effects (Simpson Angus Scale scores >3). Average steady state blood 
levels were low (71+-30 ng/ml), and associated with high D2/3 occupancies (65+-8%, 
caudate; 67+-11%, thalamus; 52+-11%, putamen). Antipsychotic clinical response occurred 
at a threshold concentration of 20ng/ml and D2/3 occupancies of 43% (caudate), 25% 
(putamen), 43% (thalamus). Extrapyramidal side effects (n=7) emerged at a threshold 
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concentration of 60ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% 
(thalamus). This study has established that, as in schizophrenia, there is a therapeutic window 
of D2/3 receptor occupancy for optimal treatment of psychosis in Alzheimer’s disease. We 
have also shown that occupancies within and beyond this window are achieved at very low 
amisulpride doses in Alzheimer’s disease due to higher than anticipated occupancies for a 
given blood drug concentration. Our findings support a central pharmacokinetic contribution 
to antipsychotic sensitivity in Alzheimer’s disease and implicate the blood brain barrier, 
which controls central drug access. Whether high D2/3 receptor occupancies are primarily 
accounted for by age- or disease-specific blood brain barrier disruption is unclear, and this is 
















Establishing that 60-80% occupancy of striatal dopamine D2/3 receptors constitutes a 
‘therapeutic window’ of antipsychotic prescribing (Farde et al., 1992, Kapur et al., 1995) was 
a landmark achievement for PET neuroreceptor imaging, and has had an enduring impact on 
the pharmacological management of schizophrenia. Optimal occupancy ranges to achieve a 
clinical response with minimal EPS have since been defined for both first and second 
generation antipsychotics (Stone et al., 2009, Uchida et al., 2011), and dosage strategies for 
young adults further refined through statistical modelling of PK and PK-occupancy data 
(Sparshatt et al., 2009, Uchida et al., 2011, Lako et al., 2013). In stark contrast, there is a 
relative absence of empirical data in older patients and clinicians are required to adopt a ‘start 
low, go slow’ approach (Pretorius et al., 2013) to reduce the associated risks. There is an 
urgent need to redress this balance, particularly in older people with dementia, in whom 
substantial morbidity and increased mortality have led to a restriction of antipsychotic use 
(Schneider et al., 2006, Jeste et al., 2008, Jennum et al., 2015, Maust et al., 2015).  
The mechanisms underlying antipsychotic sensitivity in older people and Alzheimer’s disease 
are under-researched and poorly understood (Uchida et al., 2009). Although age-related 
changes in peripheral PK, which reduce drug clearance, contribute to adverse events by 
increasing blood concentration for a given dose of drug (Feng et al., 2008), this effect is not 
consistent across antipsychotics (Bigos et al., 2008). Occupancy studies in older patients with 
schizophrenia (Uchida et al., 2009, Uchida et al., 2014, Graff-Guerrero et al., 2015) suggest 
that pharmacodynamic changes, which lower the threshold occupancy for response and EPS, 
may be important. The D2/3 receptor mediated contribution to clinical outcome has not been 
investigated within the context of psychosis in Alzheimer’s disease. 
In an imaging pilot study (Clark-Papasavas et al., 2014), we observed high (40-70%) striatal 
and thalamic D2/3 occupancy in three patients Alzheimer’s disease during low dose 
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amisulpride (50mg daily) treatment; a finding which was difficult to meaningfully interpret in 
the absence of data on amisulpride blood concentrations. We have since developed a 
population PK model for amisulpride specifically for older people, by combining data from a 
phase one, single dose study in healthy elderly with data on patients with psychosis in 
Alzheimer’s disease who were prescribed open amisulpride (25-75mg daily). There was wide 
variability in amisulpride blood concentrations (9-109ng/ml), which was largely accounted 
for by an effect of age on drug clearance (Reeves et al., 2016). However, only one patient 
achieved amisulpride blood concentrations within the currently recommended therapeutic 
range (100-319ng/ml) to avoid non-response and EPS in schizophrenia (Hiemke et al., 2011). 
The current study aimed to combine the PK model with [18F]fallypride D2/3 receptor imaging 
and clinical outcome data from the observational study and preceding imaging pilot, with the 
following objectives: 
(i) To use a population approach to characterise PK- occupancy profiles in caudate, 
putamen and thalamus  
(ii) To estimate Caverage and corresponding occupancies across the prescribed dose range, 
and establish the threshold exposure and occupancy required for clinical response 
and EPS. 
Material and Methods 
Data sources 
PK data (healthy elderly) 
Venous blood samples (n=280) were obtained from 20 healthy older participants (10 men, 
mean age = 68.7 ± 4.1) over 72 hours following a single 50mg amisulpride tablet (Hamon-
Vilcot et al., 1998). Amisulpride racemate concentrations were determined using a validated 
HPLC (high performance liquid chromatography) method (detection limit 0.5 ng/ml).  
7  
 
PK, imaging and clinical outcome data (Alzheimer’s disease) 
Data from 38 patients with probable Alzheimer’s disease (McKhann et al., 1984) included (i) 
Pharmacokinetic, imaging and clinical outcome data on 25 patients with psychotic symptoms, 
prescribed amisulpride off label as part of an open study (Research ethics comittee reference 
11/SC/0486) (ii) Imaging data on 10 antipsychotic-free patients, recruited to provide 
additional ‘pre-treatment’ data to inform model development (iii) Paired imaging and clinical 
outcome data on three patients who participated in the pilot (Research ethics committee 
reference 10/H0807/75). Patients were recruited from the South London and Maudsley NHS 
Foundation Trust. All were antipsychotic naïve, and included on the basis of having no 
history of psychiatric illness, traumatic brain injury, epilepsy, significant cardiorespiratory 
disease, needle phobia, any contraindication to amisulpride, or features suggestive of Lewy 
Body Dementia (McKeith et al., 1996). Verbal and written informed consent was obtained 
from participants, or appropriate carers where capacity was lacking. Clinical assessment, 
carried out at baseline and every two to four weeks during dose titration, included (i) 
Frequency x severity ratings for three Neuropsychiatric Inventory domains (delusions, 
hallucinations, agitation) (Cummings et al., 1994) (ii) EPS rating (Simpson Angus Scale 
scores > 3) (Simpson and Angus, 1970). Patients commenced amisulpride at a dose of 25mg 
or 50mg, (based on the preference of the prescribing clinician), which was administered as a 
single evening dose, and increased to an optimum dose (25% or greater reduction in 
symptoms and minimal EPS).  [18F]fallypride imaging was carried out at baseline (all 
patients) and at an ‘optimum’ dose (treated patients). Flexibility was built into the design 
around the timing of follow-up assessments, to account for variability in the dose titration 
regimen across prescribers. Compliance with medication (pill counts and discussion with 
carer), concomitant medication and clinical outcome (symptom ratings, side effects) were 
recorded at each visit. The timing of blood collection reflected convenience samples, which 
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coincided with follow-up assessments and/or imaging. Date, time of sample and hours since 
last dose (confirmed by a carer where possible) were recorded on the anonymised assay 
request form. Blood samples were analysed in a secure, CPA accredited laboratory (Clinical 
Toxicology Unit, Kings College Hospital). Amisulpride (racemate) blood concentrations 
were determined using validated LC-MS/MS (liquid chromatography with tandem mass 
spectrometry) method, with a detection limit of 9ng/ml. 
PET image acquisition and analysis 
Participants were scanned between 12-2.30pm, using a GE (GE Healthcare, Hatfield, UK) 
VCT Discovery PET-CT camera (full width half maximum 5mm), at St Thomas’ Hospital 
PET Centre, London. [18F]fallypride was administered via a single bolus intravenous 
injection of 250MBq. Each scan consisted of three 20 minute dynamic scans (three 
dimensional mode, each preceded by low dose CT for attenuation correction) at baseline (0--
20, 70-90, 220-240 minutes) and post-treatment (0-20, 40-60, 130-150 minutes) (Dunn et al., 
2013, Clark-Papasavas et al., 2014); shorter post-treatment scan duration reflecting the fact 
that occupancy of D2/3 receptor sites reduces the time for [18F]fallypride to achieve a 
transient equilibrium (Kegeles et al., 2008, Vernaleken et al., 2011). Image analysis was 
carried out (by EM) blind to treatment status. [18F]fallypride BPND (Innis et al., 2007)
 was 
quantified using a simplified reference tissue model with cerebellar reference region 
(Lammertsma and Hume, 1996). Preprocessing was performed using statistical parametric 
mapping version 8 (www.fil.ion.ucl.ac.uk/spm) and all other analyses using Matlab 
(www.mathworks.com). Non-attenuation corrected, three dimensional iteratively 
reconstructed PET scans (VuePoint’) were used for frame-by-frame realignment. 
Transformations were applied to attenuation corrected, filtered back projected PET images 
which were used for quantification, and attenuation corrected-VuePoint PET images used for 
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warping atlases. The cerebellum was defined using the Automated Anatomical Labeling atlas 
(Tzourio-Mazoyer et al., 2002) and regions of interest (caudate, putamen, thalamus) were 
defined using the Tziortzi atlas (Tziortzi et al., 2011). Atlases were warped to subject space 
via a [18F]fallypride template in standard  space (Dunn et al., 2013).  
Statistical analysis 
Demographic data were analysed using statistical package for social sciences version 22.0. 
Correlations were expressed as Spearman’s correlation coefficient r, and independent 
samples t-tests were used for group comparisons. PK-occupancy models were developed 
using an oral two compartment PK model (Reeves et al., 2016) (see Table 2) and an Imax 
model to describe serial [18F]fallypride BPND data in each region, as follows: BPPOST = BPPRE 
*[(1-Imax*Cc)/(Cc+IC50)], where BPPRE and BPPOST represent pre- and post-treatment BPND 
respectively; Imax, which represents the maximum inhibitory effect of amisulpride at D2/3 
receptors (1 corresponds to 100% occupancy); Cc, amisulpride blood concentration; and 
IC50, blood concentration associated with 50% Imax. NLME was implemented using 
Monolix software (version 4.33). Model parameters were estimated using a Stochastic 
Approximation Expectation Minimisation algorithm. NLME simultaneously estimates fixed 
effects (parameters which describe dose-concentration and concentration-occupancy 
relationships), and random effects, comprised of IIV (difference between individual and 
predicted model parameter values), and residual variability (system noise, dosage history 
errors and/or model misspecifications) (Ette et al., 2004). IIV for PK and occupancy 
parameters was estimated using an exponential model Pi = PTV × e
ηp where Pi is the parameter 
estimate for the ith individual, and PTV is the typical value for the parameter at the population 
level. Variability between ith individual and population parameter values (eta, ηp), was 
assumed to be normally distributed (mean of 0, variance of omega, ωη2). Residual variability 
was described using a proportional residual error model (yij = ŷij (1+ εij), where yij and ŷij 
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represents the jth observed BPND and corresponding model-predicted BPND; and εij was 
assumed to be normally distributed (mean 0, variance sigma, σ2). Covariates included age and 
weight on drug clearance (using estimates from the previously developed PK model) and 
were restricted to age, gender and MMSE (Folstein et al., 1975) for the Imax model. Models 
were evaluated using goodness-of-fit criteria, including diagnostic scatter plots, visual 
predictive checks, degree of shrinkage, change in IIV, model precision, and approximate 
likelihood ratio tests, based on log-likelihood and standard error of the Monto Carlo estimate. 
A change in log likelihood estimate was considered significant if equal to or greater than four 
(equivalent to P < 0.05, one degree of freedom), and accompanied by no change or a decrease 
in BIC (Bayesian Information Criteria).  
Model predictions were used to estimate the following: 
i) Regional occupancy for individuals with no pre-treatment imaging data, using the 
equation [(BPPRE-BPPOST)/BPPRE*100].  
ii) Average steady state blood drug concentration across the dosage interval (Caverage) and 
corresponding regional occupancies across the dose titration range.  
iii) For the purposes of direct comparison with PK-occupancy data in young adults 
(Vernaleken et al., 2004), blood concentrations required for 60% occupancy in 
caudate and putamen.  
iv) Blood drug concentration and corresponding occupanciest in caudate and putamen at 
peak (four hours post dose) and trough (24 hours post dose). 
Results 
Demographic and clinical characteristics of Alzheimer’s disease patients 
There were 28 patients in the treated group (mean age 82.1 +-6.6years; 11 (39%) men; mean 
Mini Mental State (MMSE) 17.7+-5.4), all of whom  experienced psychotic symptoms at 
baseline (26 (92.8%) delusions, 19 (67.8%) hallucinations), 20 (71.4%) associated agitation) 
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(described in Table 1); and 10 antipsychotic free patients (mean age 83.6+-3.8 years, 4 (40%) 
men, mean MMSE 20.3+-6.1)). A total of 41 blood samples (2+-0.78 per person; blood 
concentration 40.9+-27.1ng/ml) were taken during steady state treatment (25-75mg daily); 
16.2 ± 3.1 hours post dose; and after 56.9 ± 58 days treatment. During dose titration, 7 (25%) 
patients were withdrawn, due to EPS (n=5), falls (n=1), and unrelated health problems (n=1). 
Subclinical EPS, which did not lead to treatment cessation, emerged in two patients (blood 
concentrations of 39ng/ml and 88 ng/ml at the time of imaging). All patients who completed 
the study (n=21) were prescribed 50mg daily, and had achieved a mean reduction in symptom 
scores of 80 ± 27% (delusions), 95 ± 15% (hallucinations) and 84 ± 28% (agitation).  
 [18F] fallypride imaging pre- and post-treatment  
Baseline [18F]fallypride imaging (BPPRE) data was obtained in 15 patients (10 ‘antipsychotic 
free’, and five ‘treated’). Post-treatment imaging (BPPOST) data was obtained from 19 
patients, at 80 +- 58 days of treatment, 16+-2 hours post dose. Amisulpride concentration was 
42.4+-31.9 ng/ml, apart from two samples which were below the limit of quantification. 
Mean administered [18F]fallypride dose was 246 +-4.7 MBq, with no difference between pre- 
and post-treatment groups (t = -0.66, df = 32, P = 0.51). Mean BPPRE was 17.12+-3.96 in the 
caudate, 22.68+-4.83 in the putamen and 1.50+-0.36 in the thalamus. Age was correlated with 
BPPRE in the caudate (r = - 0.56, P = 0.03) and putamen (r = - 0.54, P = 0.03), but not 
thalamus (r =-0.22, P = 0.43). Mean BPPOST was 8.18+-2.70 in the caudate, 14.52+-4.40 in 
the putamen and 0.74+-0.33 in the thalamus, and showed no relationship with treatment 
duration, after adjusting for dose (partial correlation coefficient, r < 0.2, P > 0.43 for each 
region). Fig 1 shows [18F]fallypride uptake A) before and B) after amisulpride treatment.  
PK-occupancy model 
PK-occupancy parameters are shown in Table 2. Imax was 84.3% for the caudate (IC50 19.1 
ng/ml), 98.7% for the putamen (IC50 61.3 ng/ml), and 100% for the thalamus (IC50 29.5 
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ng/ml). Fixed effects were estimated with good precision, apart from IC50 for the putamen 
(relative standard error 70%). Random effects were estimated on all parameters apart from 
IC50 (not estimated in any model), and Imax (only estimated with precision for the caudate); 
with residual variability being estimated with better precision for PK (relative standard error 
5%) than Imax (relative standard error 48-58%) parameters. Base models were chosen as the 
best fit for the data, as covariate testing did not improve the model fit or precision. 
Occupancy estimates at the time of imaging (excluding patients with amisulpride 
concentrations below the limit of quantification) were 56+-13% in the caudate, 39+-17% in 
the putamen, and 59 +-12 % in the thalamus. EPS was present at a lower threshold of 45%, 
24% and 61% in caudate, putamen and thalamus respectively (Fig 2). Occupancies were 
correlated across all regions (P<0.0001; correlation coefficient r ranged from 0.77 between 
thalamus and putamen, to 0.96 between caudate and putamen); and with amisulpride 
concentration (P<0.0001; r = 0.82 for caudate and thalamus, r = 0.77 for putamen), but not 
age (r <0.2, P > 0.4 for all regions). Occupancy did not differ in those prescribed donepezil 
compared to those who were not (P > 0.25 all regions). Scatterplots of BPPRE and BPPOST 
data, visual predictive (percentile) plots and estimated occupancy at the time of imaging are 
shown in Fig 2 for A) caudate B) putamen and C) thalamus. Amisulpride concentrations 
required to achieve 60% occupancy were estimated as 48ng/ml for the caudate and 94ng/ml 
for the putamen.  
Model predicted Caverage, occupancy and clinical outcome 
Outcome was evaluated across an estimated Caverage 71+-30ng/ml (range 20-137ng/ml), and 
occupancies of 65+-8% (range 43-84%) in the caudate, 52+-11% (range 25-74%) in the 
putamen, and 67+-11% (range 43-82%) in the thalamus. Clinically meaningful responses 
(25% or more reduction in symptoms) were achieved at a lower threshold of 20.1 ng/ml, 
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corresponding to occupancies of 43% in caudate and thalamus and 26% in the putamen. EPS 
emerged at a threshold Caverage  of 60ng/ml and corresponding occupancies of 61%, 49% and 
69% for caudate, putamen and thalamus respectively. Figure 3 shows Caverage plotted against 
predicted occupancy, and separated on the basis of EPS for A) caudate B) putamen and C) 
thalamus. Model estimates for Caverage, blood concentrations at four and 24 hours post dose, 
and corresponding occupancies in caudate and putamen, are detailed in Table 3, separated on 
the basis of EPS. Caverage was higher in those with emergent EPS (77.7 +-24.0 ng/ml versus 
64.8+-32.6 ng/ml), but did not achieve significance (P = 0.37) and showed a similar pattern 
(P > 0.18) across all comparisons.   
Discussion 
Amisulpride is a highly D2/3 receptor selective antipsychotic drug for which optimal 
effective dose (400-800mg), blood concentration (100-319ng/ml), and striatal occupancy (40-
70%) have been established in schizophrenia (Sparshatt et al., 2009, Hiemke et al., 2011), but 
for which there is limited data in patients aged over 65 years. This study is the first to 
characterise the relationship between blood levels, central D2/3 occupancy and clinical 
outcome in older patients with psychosis in the context of Alzheimer’s disease. Low blood 
concentrations were associated with high central occupancies which overlapped with the 
reported therapeutic window described for young patients with schizophrenia (Bressan et al., 
2003, Sparshatt et al., 2009, Lako et al., 2013), and were associated with clinical response 
(greater than 25% reduction in psychotic symptoms) and EPS. 
Occupancy data on low dose (50-100mg) amisulpride is limited and highly variable in young 
adults, with occupancy estimates ranging from below 10% (Martinot et al., 1996, Xiberas et 
al., 2001) to 40% (la Fougere et al., 2005, Meisenzahl et al., 2008) in the striatum and 30-
40% in the thalamus (Xiberas et al., 2001). These discrepancies are partly accounted for by 
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methodological differences - imaging modality, scan duration, and timing of dose relative to 
scan (Meisenzahl et al., 2008) - but also reflect the steeper gradient of the occupancy slope at 
low blood concentrations, which means that small changes in concentration produce larger 
changes in occupancy (Vernaleken et al., 2004). Choice of tracer is an additional 
consideration, as in vitro data have shown that tracers with higher affinity (low dissociation 
constant, Kd) such as [18F]fallypride (Kd 0.03nM) require higher concentrations of 
competing drug to displace them from the receptor site than lower affinity tracers such as 
[11C]raclopride (Kd 1.9nM), resulting in lower apparent occupancies (Seeman and Van Tol, 
1995, Seeman, 2011, Seeman, 2014). In vivo, under estimation of occupancy is more 
pronounced if D2/3 receptor availability is calculated prior to the onset of a transient 
equilibrium, and is particularly relevant for the striatum, as time to equilibrium is dependent 
on the density of receptor sites (Olsson and Farde, 2001, Xiberas et al., 2001, Vernaleken et 
al., 2011). Sampling times for the current study were therefore informed both by previous 
post-treatment [18F]fallypride protocols (Kessler et al., 2006, Kegeles et al., 2008) and the 
above studies. 
Occupancies in the current study are at least as high as those previously reported, and up to 
twice as high (80% occupancy) in a proportion of patients. This is perhaps most clearly 
demonstrated by comparing our findings with those of Vernaleken et al (Vernaleken et al., 
2004), who modelled the non-linear occupancy curve for [18F]desmethoxyfallypride, and 
whose estimates for amisulpride blood concentration required to achieve 60% occupancy in 
caudate (119ng/ml) and putamen (241 ng/ml) are higher than the current study (48ng/ml and 
94 ng/ml for caudate and putamen respectively). Taking dissociation constants for the two 
tracers into account ([18F]fallypride, 0.03nM; [18F]desmethoxyfallypride, 0.34nM) 
(Mukherjee et al., 1996), if anything  we may be under-estimating the true extent of the 
differences between young adults and older patients with Alzheimer’s disease, and it will be 
15  
 
important to directly compare older and younger adults in future studies, using comparable 
methodology (tracer, sampling times and modelling approach)  
The finding of higher than anticipated occupancies for a given blood level provides the first 
in vivo evidence of a central pharmacokinetic contribution to antipsychotic sensitivity in 
Alzheimer’s disease and strongly implicates the BBB, which controls central drug access 
(Zeevi et al., 2010). Our findings are at odds with occupancy studies in older patients with 
schizophrenia (Uchida et al., 2009, Graff-Guerrero et al., 2015), in whom the relationship 
between blood concentration and occupancy was found to be similar to that observed in 
young people. Whether these differences are explained by the extreme age of participants in 
the current study, their diagnosis, or possibly both, is unclear, but there is certainly evidence 
that BBB integrity is disrupted (increased permeability and reduced expression of efflux 
transporters) with age and more profoundly affected by Alzheimer’s disease (Zeevi et al., 
2010). A further consideration is our choice of amisulpride, which has low lipophilicity, 
shows poor BBB penetration relative to other antipsychotics (Natesan et al., 2008) and has 
been identified as a substrate for several BBB transporters, including the efflux transporter p-
glycoprotein (Schmitt et al., 2012), and the widely expressed (brain, biliary, renal) organic 
cation transport system (Dos Santos Pereira et al., 2014, Sekhar G, 2016). These properties 
may mean that amisulpride is a more sensitive tool with which to explore BBB disruption 
than antipsychotics previously studied.  
We cannot rule out the possibility that age and/or disease-specific changes in distribution and 
clearance of amisulpride within the central nervous system (Uchida et al., 2009), which could 
potentially increase synaptic levels of amisulpride, may have contributed to the high observed 
occupancies. Reduced competition with amisulpride at D2/3 receptor sites, due to age-related 
reductions in endogenous dopamine release (Volkow et al., 1994), also needs to be 
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considered, although the magnitude of such changes would not be sufficient to account for 
the extent of the differences observed between our findings and those of previous studies.  
The clinical dataset was limited by small sample size, sparse blood sampling and absence of 
pre-treatment imaging in a proportion of patients. It was thus important to combine the 
dataset with a richly sampled phase 1 study, to fully parameterise the PK model and, with the 
addition of paired scans from the imaging pilot, more precisely model PK-occupancy 
profiles. Model-based estimation of BPPRE is an established method to calculate occupancy 
(Kim et al., 2011), and one which produced the anticipated occupancy gradients for 
amisulpride - thalamus > striatum (Xiberas et al., 2001, Bressan et al., 2003) and caudate > 
putamen (Vernaleken et al., 2004) - in the current study.  
Use of a population approach allowed estimation of average, peak and trough blood drug 
concentrations, and corresponding occupancies across the dose titration range in all 
individuals, including those who were withdrawn due to EPS. The fact that the threshold 
occupancy for EPS in the striatum was lower than that observed in young people is broadly 
consistent with data on older patients with schizophrenia (Uchida et al., 2009, Uchida et al., 
2014, Graff-Guerrero et al., 2015) and suggests there may be an additional pharmacodynamic 
contribution to EPS. The absence of significant differences between maximal and minimal 
blood drug concentration and occupancy when the group was separated on the basis of EPS 
does not necessarily rule out a contribution to emergent side effects, as the study was not 
sufficiently powered to detect such differences. The population approach will be used to 
model and further explore the relationship of PK (average, peak and trough) and occupancy 
with EPS in future analyses. 
Other limitations need to be considered, including variable length of follow-up, due to 
technical (cyclotron, radiochemistry) issues, which delayed post-treatment imaging in a 
proportion of patients. Although this could have potentially impacted on post-treatment D2/3 
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receptor availability, this is unlikely to have affected our findings, as BPPOST was not 
correlated with treatment duration. Non-adherence is a potential confound when modelling 
the relationship between PK, occupancy, response and toxicity and is a common issue in 
people with cognitive impairment (Jankowska-Polanska et al., 2016). Although compliance 
was closely monitored and facilitated both by carers and clinical teams, tablet counts and 
self-report are not wholly reliable (Blaschke et al., 2012) and it is likely that  ‘undetectable’ 
amisulpride concentrations (below the 9ng/ml lower limit of the assay sensitivity) in two 
patients at the time of imaging reflect imperfect compliance. It is not possible to fully 
quantify the influence of non-adherence on amisulpride dose individualisation without further 
population modelling of clinical outcome data (Assawasuwannakit et al., 2016). However, 
the terminal half life of amisulpride (which varies between 12.4 hours in those aged 65 years 
and 22.7 hours in those aged 85 years) (Reeves et al., 2016), and the fact that occupancy 
decreases at a slower rate than blood drug concentration (Tauscher et al., 2002, Takano et al., 
2004, Sekine et al., 2011), would suggest that amisulpride is relatively ‘forgiving’ of 
imperfect adherence (Urquhart, 1997), as the duration of effect is likely to exceed the dosage 
interval. 
The decision not to obtain volumetric MRI for co-registration with PET data was both 
pragmatic and scientific, based on our previous experience of imaging older and cognitively 
impaired older patients, in whom close confinement is poorly tolerated (Clark-Papasavas et 
al., 2014), and the fact that D2/3 receptor binding can be reliably quantified using an atlas-
based approach (Dunn et al., 2013, Clark-Papasavas et al., 2014). However, the fact that 
templates originated from young adults could have impacted upon the warping process, 
particularly in smaller, noisier regions (Dunn et al., 2013); and partial volume effects (Morris 
et al., 1999) may have further affected the accuracy of tracer quantification. The absence of 
volumetric MRI meant that we were unable to investigate the relationship between occupancy 
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and disease stage or vascular pathology and this should be investigated in future studies. 
Neither was the study sufficiently powered to examine the impact of concomitant medication, 
including donepezil, on PK-occupancy models. However, we have previously shown no 
significant effect of donepezil on striatal D2/3 receptor availability in patients with mild to 
moderate Alzheimer’s disease, using [11C] raclopride PET (Reeves et al., 2010) and similarly 
observed no differences in occupancy in relation to donepezil use in the current study. The 
issue of diagnosis is important when psychosis is present in the context of a dementia, and 
careful screening was thus carried out to exclude patients with suspected Lewy Body 
Dementia, including case note review, clinical assessment and, where appropriate, referral for 
dopamine transporter imaging (McKeith et al., 1996). While we cannot completely rule out 
the possibility that Lewy body pathology may have contributed to the observed drug 
sensitivity, EPS are sufficiently explained by the higher than anticipated occupancies.  
In summary, this study has shown that, similar to schizophrenia, there is a therapeutic 
window of D2/3 receptor occupancy for the optimal treatment of psychosis in Alzheimer’s 
disease. Furthermore, we have clearly demonstrated that occupancies within and beyond this 
window are achieved at very low amisulpride doses and correspondingly low blood 
concentrations, due to higher than anticipated occupancies.  These data provide the first in 
vivo evidence to support a central pharmacokinetic contribution to antipsychotic drug 
sensitivity, in a representative group of older people with Alzheimer’s disease. Whether these 
findings are primarily explained by age or disease-specific BBB disruption, or a combination 
of both is unclear and this is an important avenue for future investigation. The population 
approach will be extended to clinical outcome data in future analyses, with the aim of 
establishing the relationship of PK and regional D2/3 receptor occupancy with response 
across individual symptom domains (delusions, hallucinations, agitation) and EPS, establish 
the target amisulpride concentration and D2/3 occupancy range required to optimally treat 
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psychosis in Alzheimer’s disease, and provide clear guidance on age and weight based dose 
adjustments. 
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Figure 1. Representative [18F] Fallypride images 
[18F]Fallypride uptake images are shown in a 69 year old woman with Alzheimer’s disease, 
from left to right, A) before B) after 56 days treatment with amisulpride 50mg/day, and from 













Figure 2. PK-occupancy model and predictions 
From left to right, in A) caudate B) putamen C) thalamus and from top  to bottom:  [18F]fallypride uptake pre and post treatment (lines 
connecting paired scans); visual predictive checks (VPC), 95% prediction intervals around 50th (pink) and 90th (blue) percentiles, overlaid to 






Figure 3. Model estimated Caverage and corresponding occupancy 
From left to right, in A) caudate B) putamen C) thalamus, model estimates for Caverage across the dose titration range are plotted against 






































* compliance aided by dossette box and/or informal and formal carers 
† frequency x severity scores for the relevant Neuropsychiatric Inventory domain (maximum score of 12) 
 
Table 1. Demographic and clinical characteristics of treated patients (n=28) 
 
Characteristic Values 
Age, Mean +-SD (range) 82.1+-6.6 (69-92) 
Men, Number (%)  11 (39) 
Mini Mental State Examination, Mean +- SD (range) 17.7+-5.4 (7-26) 
Ethnicity, Number (%)  
      White British or Other 16 (57) 
      Black African, Caribbean or Other 12 (43) 
Living status, Number (%)  
     Living alone * 8 (29) 
     Living with family 17 (61) 
     Care Home 3 (10) 
Prescribed medication, Number (%)  
     Donepezil 9 (32) 
     Memantine 4 (14) 
     Antidepressant 3 (10) 
     Benzodiazepines 4 (14) 
Symptom rating at baseline, Mean +-SD (range)  
    Delusions † 8.5+-4 (0-12) 
    Hallucinations † 5.8+-4.8 (0-12) 
    Agitation † 5.5+-4.4 (0-12) 
Simpson Angus Scale  0.25+-0.6 (0-2) 
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Table 2. Pharmacokinetic (PK)-D2/3 Receptor Occupancy Models 
Parameter Estimate (RSE%) Interindividual variability % (RSE%) Residual variability % (RSE%) 
PK model (oral 2 compartment)   17.6 (5) 
Absorption constant, ka (/L) 0.84 (18) 46.8 (23)  
Clearance from central compartment, Cl (L/hr) *† 49.2 (7) 49.5 (10)  
Central volume of distribution, V1 (L) 452 (15) 46.2 (22)  
Inter-compartmental clearance, Q (L/hr) 112 (16) 65.2 (19)  
Peripheral volume of distribution, V2 (L) 
 
759 (11) 48.7 (17)  
PK- Caudate Imax model   15.3 (58) 
BPPRE 17.3 (5) 13.5 (40)  
Imax (%) 83.4 (11) 8.9 (36)  
IC50 (ng/ml) 19.1 (40) not estimated  
-2 x log likelihood  = -2104  
Bayesian Information Criteria = - 1999 
 
   
PK- Putamen Imax model   14.4 (50) 
BPPRE 23.0 (5) 12.1 (41)  
Imax (%) 98.7 (33) 9.6 (67)  
IC50 (ng/ml) 61.3 (70) not estimated  
-2x log likelihood = - 2081 
 Bayesian Information Criteria = - 1975 
 
   
PK-Thalamus Imax model   17.2 (48) 
BPPRE 1.54 (6) 17.5 (33)  
Imax % 100 (13) not estimated  
IC50 (ng/ml) 29.5 (42) not estimated  
-2x log likelihood =- 2262 
Bayesian Information Criteria =- 2161 
   
* Allometric scaling (power 0.75) fixed for weight on CL; † Power effect of -3.21 estimated for age on CL 
BPPRE  - baseline [18F] fallypride binding potential 
Imax - maximum inhibitory effect, expressed as a percentage D2/3 receptor occupancy 
IC50 - amisulpride concentration needed to obtain 50% Imax  




EPS, extrapyramidal side effects 
 





Table 3. Model predicted blood drug concentration and striatal D2/3 receptor occupancy 
Model estimate (mean +-SD) No EPS (n=21) EPS (n=7) P* 
Average:    
    Blood drug concentration (ng/ml) 64.8+-32.6 77.7+-24.0 0.37 
    Occupancy, caudate (%) 62.7+-10.1 66.1+-4.1 0.43 
    Occupancy, putamen (%) 
 
48.7+-13.6 54.1+-7.0 0.34 
Peak (4 hours post dose)    
    Blood drug concentration (ng/ml) 306.7+-175.8 361.4+-138.9 0.48 
    Occupancy, caudate (%) 78.3+-6.14 78.7+-2.2 0.91 
    Occupancy, putamen (%) 
 
79.2+-82.8 82.8+-4.9 0.45 
Trough (24 hours post dose)     
    Blood drug concentration (ng/ml) 36.0+-24.0 41.1+-19.6 0.63 
    Occupancy, caudate (%) 50.2+-15.2 54.7+-8.7 0.49 
    Occupancy, putamen (%) 33.9+-15.9 37.9+-10.9 0.57 
